Astex Pharmaceuticals Announces Oral Presentation of SGI-110 Results From Phase 1/2 MDS and AML Study at ASH

Astex Pharmaceuticals Announces Oral Presentation of SGI-110 Results From Phase 1/2 MDS and AML Study at ASH

Astex Pharmaceuticals, Cancer Research Technology and Newcastle University Sign Strategic Drug Discovery Alliance

Astex Pharmaceuticals, Cancer Research Technology and Newcastle University Sign Strategic Drug Discovery Alliance

Astex Scientists Publish the Discovery of Novel Allosteric Modulators for the Key Therapeutic Targets HCV NS3 and PKM2 in Nature Journals

Astex Scientists Publish the Discovery of Novel Allosteric Modulators for the Key Therapeutic Targets HCV NS3 and PKM2 in Nature Journals

Astex Pharmaceuticals Announces the Appointment of President Harren Jhoti, PhD to the BioIndustry Association Board of Directors

Astex Pharmaceuticals Announces the Appointment of President Harren Jhoti, PhD to the BioIndustry Association Board of Directors

Astex Pharmaceuticals Earns $5 Million for First Commercial Sale of DACOGEN(R) in the European Union

Astex Pharmaceuticals Earns $5 Million for First Commercial Sale of DACOGEN® in the European Union

Astex Pharmaceuticals Announces Initiation of SGI-110 Phase 2 Trial in Platinum-Resistant Recurrent Ovarian Cancer Patients

Astex Pharmaceuticals Announces Initiation of SGI-110 Phase 2 Trial in Platinum-Resistant Recurrent Ovarian Cancer Patients